Cohort A focused on patients with CLE or SLE with active lupus rash and evaluated organ-specific disease activity using the Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity ...

Immunovant faces high R&D costs, limited cash runway, and unproven clinical edge despite pipeline progress and deeper IgG ...

These manifestations are often part of the systemic activity or flare, which can be painful and have a considerable impact on quality of life,” said principal investigator Prof. Eric Morand, from ...

Merck KGaA has shed more light on the failure of its lupus drug in one cohort of patients, while pointing to secondary ...

Cohort B of the Phase 2 study indicates all doses of enpatoran were associated with higher BICLA response rates compared with placebo, though the ...

The Johns Hopkins Department of Dermatology is seeking volunteers with cutaneous lupus to participate in a research study ...

Cohort analyses from the WILLOW study reveal clear proof of concept in patients with CLE and SLE with active lupus rash, showing clinically meaningful improvement in disease activity at Week 16 ...

Results will be presented at the 16 th International Congress on Systemic Lupus Erythematosus (LUPUS 2025), taking place May 21-24 in Toronto. WILLOW is a global, multicenter, randomized, ...